US equities |
SPCX $171.09 ▲+0.00% NVDA $238.90 ▲+0.00% MU $1,063.96 ▲+0.00% SDEV $3.94 ▲+0.00% SNDK $1,704.16 ▲+0.00% AMD $631.75 ▲+0.00% SKHY $195.02 ▲+0.00% TSLA $378.73 ▲+0.00%
FinancialContent

DBV Technologies S.A. - American Depositary Shares (NQ:DBVT)

10.44 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DBV Technologies S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
3 Biopharmaceutical Stocks Bucking the Sell-Off
Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence. 
Via MarketBeat
Topics World Trade
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why DBV Technologies (DBVT) Stock Is Skyrocketing ↗
DBV Technologies secured up to $306.9M to advance its Viaskin Peanut program. The funding supports FDA submission, commercialization and ongoing pediatric peanut allergy treatment research. 
Via Benzinga
News headline image
Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected ↗
 
Via Benzinga
Topics Economy
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets' ↗
U.S. stock futures fell on Friday after two consecutive days of decline on Wednesday and Thursday. Futures of benchmark indices were lower. 
Via Benzinga
News headline image
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids ↗
DBV Technologies secures FDA guidance for Accelerated Approval of its Viaskin Peanut patch, advancing treatment for toddlers with peanut allergies through pivotal trials. 
Via Benzinga
News headline image
Wall Street Poised To Open Lower A Day After Nasdaq's Record Close Above 20,000: Expert Flags 'Deterioration Under The Surface' As 117 S&P 500 Stocks Hit New Monthly Lows ↗
U.S. stock futures declined on Thursday in premarket hours after hitting fresh highs on Wednesday. S&P 500, Dow, Nasdaq 100 & R2K were down. 
Via Benzinga
Topics Stocks
News headline image
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Plan to Implement ADS Ratio Change
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Reports Third Quarter 2024 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Tesla To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
Via AB Newswire
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Penny Stock DBV Technologies Advances Viaskin Peanut Allergy Patch With FDA Approval Pathway ↗
DBV Technologies progresses with regulatory efforts for its Viaskin Peanut patch in the U.S. and Europe, while financial concerns loom as the company seeks additional funding to continue its... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >